Related Experiment Video

Updated: May 13, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Novel agents in the treatment of pancreatic adenocarcinoma

Anastasios Dimou1, Konstantinos N Syrigos, Muhammad Wasif Saif

  • 1Department of Internal Medicine, Albert Einstein Medical Center, Philadelphia, PA, USA.

JOP : Journal of the Pancreas
|March 12, 2013
PubMed

Insights

Researchers evaluated novel pancreatic cancer treatments. FG-3019 and ASG-5ME showed promise in early trials, while tanespimycin was ineffective, warranting further investigation of the former two agents.

Area of Science:

  • Oncology
  • Gastroenterology
  • Clinical Pharmacology

Background:

  • Pancreatic adenocarcinoma has a poor patient prognosis, necessitating the development of novel therapeutic agents and strategies.
  • Connective tissue growth factor (CTGF) and SLC44A4 are implicated in pancreatic cancer biology.
  • Heat shock protein 90 (HSP90) is a target in cancer therapy.

Purpose of the Study:

  • To present results from clinical trials of three novel compounds targeting pancreatic cancer.
  • To evaluate the safety and potential efficacy of FG-3019, ASG-5ME, and tanespimycin in pancreatic cancer patients.

Main Methods:

  • Phase I clinical trial of FG-3019, an inhibitor of connective tissue growth factor (CTGF).
  • Phase I clinical trial of ASG-5ME, an antibody targeting SLC44A4 with a chemotherapy conjugate.
  • Phase II clinical trial of tanespimycin, a heat shock protein 90 (HSP90) inhibitor, in first-line treatment.

Main Results:

  • FG-3019 demonstrated relative safety in a Phase I study (Abstract #213).
  • ASG-5ME was found to be safe at appropriate doses in a Phase I trial (Abstract #176).
  • Tanespimycin showed no effectiveness as a first-line treatment in a Phase II study (Abstract #245).

Conclusions:

  • FG-3019 and ASG-5ME warrant further investigation for potential activity in pancreatic cancer patients.
  • Tanespimycin was not effective in the studied first-line treatment setting for pancreatic cancer.
  • Ongoing research into novel agents is crucial for improving outcomes in pancreatic adenocarcinoma.

More Related Videos

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

An Orthotopic Resectional Mouse Model of Pancreatic Cancer07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.